4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3
Open Access
- 28 June 2024
- journal article
- research article
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 39, 101765
Abstract
No abstract availableKeywords
Funding Information
- NIDDK (K08DK115833)
- Oxalosis and Hyperoxaluria Foundation
- Alnylam Pharmaceuticals
- National Institutes of Health (K01DK114332)
This publication has 15 references indexed in Scilit:
- Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)Urolithiasis, 2023
- Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluriaKidney International, 2022
- Regulation of human 4-hydroxy-2-oxoglutarate aldolase by pyruvate and α-ketoglutarate: implications for primary hyperoxaluria type-3Biochemical Journal, 2019
- Metabolite diagnosis of primary hyperoxaluria type 3Pediatric Nephrology, 2018
- Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assayBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibitionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Primary hyperoxaluria type III—a model for studying perturbations in glyoxylate metabolismJournal of Molecular Medicine, 2012
- Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type IIIThe American Journal of Human Genetics, 2010
- All in the family: aldose reductase and closely related aldo-keto reductasesCellular and Molecular Life Sciences, 2004